Repatha Approved for Single Monthly Injection

–New hands-free system replaces three sequential shots The FDA has approved a device that can deliver a single monthly injection of evolocumab (Repatha), the cholesterol-lowering PCSK9 inhibitor manufactured by Amgen. Repatha is currently administered by subcutaneous injection in a 140-mg dose every 2 weeks or as a 420 mg monthly dose. Until now, the monthly...Click here to continue reading...
Source: CardioBrief - Category: Cardiology Authors: Tags: People, Places & Events cholesterol PCSK9 Repatha Source Type: blogs